For the Inventor, By the Inventor

Enter assignee name

Sunnyvale, CA, United States of America

Pharmacyclics, Inc.

USPTO Granted Patents = 193

CIPO Patents = 10

EPO Patents = 23

Trademarks = 10

Forward Citations = 6,162

Loading Chart...

Loading Chart...

113 inventors (with patents filed for the assignee):

Erik J Verner (65 out of 83 patents)

Lee Honigberg (52 out of 53 patents)

Joseph J Buggy (46 out of 51 patents)

4. David J Loury (43 out of 46 patents)

5. Tarak D Mody (39 out of 54 patents)

6. Zhengying Pan (39 out of 39 patents)

7. Wei Yu Chen (28 out of 113 patents)

8. Jonathan L Sessler (26 out of 87 patents)

9. Darren Magda (24 out of 39 patents)

10. Norbert Purro (19 out of 19 patents)

11. Sriram Balasubramanian (14 out of 15 patents)

12. Mark Stephen Smyth (14 out of 39 patents)

13. Laurence Elias (13 out of 16 patents)

14. Erick A Goldman (13 out of 25 patents)

15. David Dale Wirth (13 out of 23 patents)

Core Competencies:

Bruton's Tyrosine Kinase

Kinase Inhibitors

Graft Versus Host Disease

HER2 Amplified Cancer

Pharmaceutical Formulations

Crystalline Forms

Resistance Associated Mutations

Fibrosis Treatment

Solid Tumors

Purinone Compounds

Pyrazolo Compounds

Pyrrolopyrimidine Compounds

193 patents: Sort by Forward Citations

1. 11672803 - Use of inhibitors of Brutons tyrosine kinase (Btk) (2023-06-13),

2. 10961251 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2021-03-30),

3. 10954567 - Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) (2021-03-23),

4. 10898461 - Salts of 3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same (2021-01-26),

5. 10828259 - Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor (2020-11-10),

6. 10752634 - Crystalline forms of a brutons tyrosine kinase inhibitor (2020-08-25),

7. 10751342 - Use of inhibitors of Bruton's tyrosine kinase (Btk) (2020-08-25),

8. 10695350 - Methods of treating and preventing graft versus host disease (2020-06-30),

9. 10653696 - Use of inhibitors of bruton's tyrosine kinase (BTK) (2020-05-19),

10. 10478439 - Use of inhibitors of bruton's tyrosine kinase (Btk) (2019-11-19),

11. 10463668 - Methods of treating and preventing graft versus host disease (2019-11-05),

12. 10294232 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-05-21),

13. 10294231 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-05-21),

14. 10266540 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-04-23),

15. 10226466 - Methods of treating fibrosis (2019-03-12),

Pharmacyclics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of cancer. With a focus on targeted therapies, Pharmacyclics aims to improve patient outcomes and quality of life. Visit their website for more information.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

193 Patents

#24 in Sunnyvale, CA

#477 in California

#2,057 in US

#4,238 in the World

Sunnyvale, CA, United States of America

Pharmacyclics, Inc.

Forward Citations = 6,162

113 inventors:

Erik J Verner (65 out of 83 patents)

Lee Honigberg (52 out of 53 patents)

Joseph J Buggy (46 out of 51 patents)

4. David J Loury (43 out of 46 patents)

5. Tarak D Mody (39 out of 54 patents)

Please report any incorrect information to support@idiyas.com

Loading…